West Chester Capital Advisors Inc. Invests $807,000 in Danaher Co. (DHR)

West Chester Capital Advisors Inc. bought a new stake in Danaher Co. (NYSE:DHR) in the 4th quarter, Holdings Channel reports. The firm bought 8,548 shares of the conglomerate’s stock, valued at approximately $807,000. Danaher accounts for about 0.8% of West Chester Capital Advisors Inc.’s holdings, making the stock its 25th largest position.

A number of other institutional investors and hedge funds also recently bought and sold shares of the business. BlackRock Inc. increased its position in Danaher by 4.6% during the 4th quarter. BlackRock Inc. now owns 40,984,366 shares of the conglomerate’s stock worth $3,804,169,000 after purchasing an additional 1,789,474 shares during the period. Parnassus Investments CA grew its holdings in shares of Danaher by 0.3% in the 3rd quarter. Parnassus Investments CA now owns 9,796,584 shares of the conglomerate’s stock worth $840,351,000 after acquiring an additional 29,381 shares during the period. Flossbach Von Storch AG grew its holdings in shares of Danaher by 17.2% in the 3rd quarter. Flossbach Von Storch AG now owns 6,776,921 shares of the conglomerate’s stock worth $581,324,000 after acquiring an additional 994,902 shares during the period. Dimensional Fund Advisors LP grew its holdings in shares of Danaher by 1.4% in the 3rd quarter. Dimensional Fund Advisors LP now owns 4,630,035 shares of the conglomerate’s stock worth $397,144,000 after acquiring an additional 63,327 shares during the period. Finally, Findlay Park Partners LLP grew its holdings in shares of Danaher by 52.9% in the 3rd quarter. Findlay Park Partners LLP now owns 4,117,348 shares of the conglomerate’s stock worth $353,186,000 after acquiring an additional 1,425,000 shares during the period. 77.05% of the stock is owned by hedge funds and other institutional investors.

Danaher Co. (DHR) opened at $97.34 on Wednesday. The company has a market capitalization of $67,946.36, a PE ratio of 27.58, a P/E/G ratio of 2.05 and a beta of 1.04. Danaher Co. has a 52 week low of $78.97 and a 52 week high of $104.82. The company has a quick ratio of 1.05, a current ratio of 1.43 and a debt-to-equity ratio of 0.39.

Danaher (NYSE:DHR) last posted its quarterly earnings results on Tuesday, January 30th. The conglomerate reported $1.19 EPS for the quarter, topping the Zacks’ consensus estimate of $1.16 by $0.03. The business had revenue of $5.09 billion during the quarter, compared to the consensus estimate of $4.97 billion. Danaher had a return on equity of 11.36% and a net margin of 13.60%. The company’s revenue for the quarter was up 10.9% compared to the same quarter last year. During the same period last year, the firm earned $1.05 earnings per share. analysts anticipate that Danaher Co. will post 4.37 EPS for the current fiscal year.

The firm also recently announced a quarterly dividend, which will be paid on Friday, April 27th. Shareholders of record on Thursday, March 29th will be issued a $0.16 dividend. This represents a $0.64 dividend on an annualized basis and a yield of 0.66%. This is a boost from Danaher’s previous quarterly dividend of $0.14. Danaher’s dividend payout ratio (DPR) is currently 15.86%.

In other Danaher news, SVP Angela S. Lalor sold 42,988 shares of the firm’s stock in a transaction dated Friday, February 2nd. The shares were sold at an average price of $102.29, for a total value of $4,397,242.52. Following the transaction, the senior vice president now owns 82,008 shares of the company’s stock, valued at $8,388,598.32. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, CFO Daniel L. Comas sold 62,989 shares of the firm’s stock in a transaction dated Thursday, February 1st. The stock was sold at an average price of $101.96, for a total transaction of $6,422,358.44. Following the completion of the transaction, the chief financial officer now directly owns 227,805 shares in the company, valued at approximately $23,226,997.80. The disclosure for this sale can be found here. Insiders sold 237,043 shares of company stock worth $24,194,886 in the last three months. 12.20% of the stock is currently owned by corporate insiders.

A number of equities research analysts have commented on DHR shares. Citigroup increased their target price on Danaher to $107.00 and gave the company a “buy” rating in a report on Friday, December 15th. Robert W. Baird reaffirmed a “buy” rating and issued a $99.00 target price on shares of Danaher in a research report on Friday, December 15th. Credit Suisse Group reissued a “hold” rating and issued a $99.00 price objective on shares of Danaher in a research report on Tuesday, December 19th. Zacks Investment Research lowered Danaher from a “buy” rating to a “hold” rating in a research report on Tuesday, December 19th. Finally, Evercore ISI started coverage on Danaher in a research report on Wednesday, January 3rd. They issued an “outperform” rating on the stock. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, fifteen have issued a buy rating and one has given a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and an average target price of $100.68.

ILLEGAL ACTIVITY WARNING: This news story was reported by StockNewsTimes and is the property of of StockNewsTimes. If you are reading this news story on another publication, it was illegally stolen and reposted in violation of United States and international copyright law. The legal version of this news story can be read at https://stocknewstimes.com/2018/02/21/west-chester-capital-advisors-inc-invests-807000-in-danaher-co-dhr.html.

Danaher Profile

Danaher Corporation (Danaher) designs, manufactures and markets professional, medical, industrial and commercial products and services. The Company operates through four segments: Life Sciences, which offers a range of research tools that scientists use to study the basic building blocks of life, including genes, proteins, metabolites and cells, in order to understand the causes of disease, identify new therapies and test new drugs and vaccines; Diagnostics; which offers analytical instruments, reagents, consumables, software and services; Dental, which provides products that are used to diagnose, treat and prevent disease and ailments of the teeth, gums and supporting bone, and Environmental & Applied Solutions, which consists of various lines of business, including water quality and product identification.

Want to see what other hedge funds are holding DHR? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Danaher Co. (NYSE:DHR).

Institutional Ownership by Quarter for Danaher (NYSE:DHR)

Receive News & Ratings for Danaher Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Danaher and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply